Chemoradiation for invasive cervical cancer in elderly patients: Outcomes and morbidity

Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
International Journal of Gynecological Cancer (Impact Factor: 1.95). 12/2007; 18(1):95-103. DOI: 10.1111/j.1525-1438.2007.00967.x
Source: PubMed


Age may impact survival and treatment in cervical cancer patients. We sought to determine if treatment and survival were different in elderly patients and whether chemoradiation increased morbidity. We performed a retrospective chart review to identify patients treated with definitive radiation therapy at the University of Iowa Hospitals and Clinics between 1997 and 2001. Three hundred sixty-four patients had a new diagnosis of invasive cervical cancer, of which 150 patients were treated with radiation. We excluded patients treated postoperatively or with palliative intent, leaving 96 patients treated with definitive radiation therapy. Patients were divided into two age categories: elderly (>/=65) and nonelderly (<65). We compared these groups with respect to treatment received, morbidity, and survival. Sixty-nine (72%) women were less than 65 years old, and 27 (28%) women were greater than or equal to 65 years old. Chemoradiation was associated with decreased mortality (P < 0.01). The decrease in mortality did not differ between the two age cohorts (all causes: P = 0.66; cancer specific: P = 0.65), nor was there a difference in the complication rate due to chemoradiation (P = 0.70). Although elderly patients were more likely to be diagnosed with nonsquamous histologies (P < 0.01), their odds of receiving chemoradiation were 0.35 (95% CI: 0.13-0.90) times the odds for nonelderly. Elderly cervical cancer patients more often have nonsquamous histology and are likely to receive only radiation therapy compared to younger patients. Treatment with chemoradiation was associated with similar survival increases in both age cohorts. Complication rates between the two were similar. Chemoradiation should be considered in elderly patients with invasive cervical cancer.

Download full-text


Available from: Brian J Smith, Nov 13, 2014
9 Reads
  • Source
    • "One explanation for unfavorable prognosis might be the elderly present with more advanced tumor stages as shown in previous studies (Brun et al. 2003). In the present study, however, the elderly did neither present with more advanced tumor stages nor with a higher rate of prognostically unfavorable adenocarcinoma which agrees with other reports (Goodheart et al. 2008; Mitchell et al. 1998). In this series, both age cohorts revealed node metastases in 50–60% of all patients which is much higher than in other reports (Rose et al. 1999; Eifel et al. 2004) and will have contributed to the unfavorable overall survival. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the impact of age on treatment-related acute morbidity, on modifications of drug doses and radiotherapy and on disease-free and overall survival in non-elderly and elderly with high-risk cervical cancer treated with concurrent radiochemotherapy following laparoscopic surgery. One hundred and two patients with high-risk FIGO I - IVA cervical cancer (77 non-elderly [< 60 years] and 25 elderly [≥ 60 years]) were treated by radical hysterectomy with lymphadenectomy (n = 91) and postoperative radiochemotherapy or radical radiochemotherapy alone after laparoscopic lymph node dissection (n = 11) patients received five to six cycles of cis-platin, 40 mg/sqm weekly, given concurrently to pelvic radiotherapy of 45-50.4 Gy in 5-6 weeks. Paraaortic radiotherapy with 45 Gy was performed when laparoscopic staging revealed paraaortic node metastases. Acute morbidity was prospectively scored weekly. Toxicity-related protocol violations (treatment breaks or dose reduction) were related with age, 5-year overall survival (OS) and progression-free survival (PFS) rates. Clinical stages and histologic subtypes were equally distributed. Grade 3/4 leukopenia, anemia, diarrhea and nausea occurred more frequently in the elderly. 16 (22%) non-elderly and 6 (25%) elderly needed a modification of drug dose. 10/77 (13%) non-elderly patients and 11/25 (44%) of the elderly needed an unscheduled treatment break (p = 0.002). OS and PFS were not different between age groups. The 5-year OS rate was 47 ± 6% for non-elderly patients and 45 ± 10% for the elderly. Patients with/without treatment breaks had a 5-year OS rate of 39 ± 11%/48 ± 6%. The 5-year PFS rate is 49 ± 6% for non-elderly patients and 47 ± 11% for the elderly. Patients with/without treatment breaks had a 5-year PFS probability of 50 ± 12%/48 ± 6%. FIGO stage retains its prognostic significance irrespective of age. Concurrent radiochemotherapy caused slightly higher acute toxicity with increasing age. Adjustment of treatment intensity was more frequent in the elderly but did not result in detrimental outcome figures.
    Journal of Cancer Research and Clinical Oncology 03/2011; 137(3):481-8. DOI:10.1007/s00432-010-0903-y · 3.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a method for assigning upper level gene ontology terms (GO categories) to genes using relevant documents. This method represents each gene as a vector using relevant documents to the gene. Then, binary classifiers are made for the GO categories using such supervised learning methods as support vector machines and maximum entropy method. We applied this method for assigning GO categories to yeast genes and achieved an average F-measure of 0.67, which is > 0.3 higher than the existing method developed by Raychaudhun et al. We also applied this method to genome-wide annotation for yeast by all GO Slim categories provided by SGD and achieved average F-measures of 0.58, 0.72, and 0.60, respectively, for the three GO parts: cellular component, molecular function, and biological process.
    Computational Systems Bioinformatics Conference, 2004. CSB 2004. Proceedings. 2004 IEEE; 09/2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With respect to cervical cancer management, Finland and the Netherlands are comparable in relevant characteristics, e.g., fertility rate, age-of-mother at first birth and a national screening programme for several years. The aim of this study is to compare trends in incidence of and mortality from cervical cancer in Finland and the Netherlands in relation to the introduction and intensity of the screening programmes. Therefore, incidence and mortality rates were calculated using the Cancer Registries of Finland and the Netherlands. Data on screening intensity were obtained from the Finnish Cancer Registry and the Dutch evaluation centre at ErasmusMC-Rotterdam. Women aged 30-60 have been screened every 5 years, in Finland since 1992 and in the Netherlands since 1996. Screening protocols for smear taking and referral to the gynaecologist are comparable. Incidence and mortality rates have declined more in Finland. In 2003, age-adjusted incidence and mortality in Finland were 4.0 and 0.9 and in the Netherlands 4.9 and 1.4 per 100,000 woman-years, respectively. Excess smear use in the Netherlands was estimated to be 24 per 1,000 women during a 5-year interval compared to 121 in Finland. The decline in mortality in Finland seems to be almost completely related to the screening programme whereas in the Netherlands it was initially considered to be a natural decline. Differences in risk factors might also play a role: the Netherlands has higher population density and higher percentages of immigrants and (female) smokers. The greater excess smear use in Finland might also have affected incidence.
    International Journal of Cancer 04/2007; 122(8):1854-8. DOI:10.1002/ijc.23276 · 5.09 Impact Factor
Show more